Description
Product Specifications
- Product: Tirzepatide 30mg
- Compound / formulation: Tirzepatide (LY3298176)
- Labeled quantity / volume: 30mg per vial
- Physical form: White lyophilized powder
- Research focus: Metabolic Research, Glucose Regulation, Appetite Regulation, Incretin Signaling
- Available batch identifiers: White cap, batch T30-HOP-0826
- SKU: HOP-tirzepatide-30mg
- Intended classification: Laboratory research only
Independent Laboratory Testing
White cap — Janoshik Analytical, report #231265 — Batch T30-HOP-0826
- Compound reported: Tirzepatide
- Measured content, sample 1: 33.86mg
- Purity, sample 1: 99.649%
- Measured content, sample 2: 31.84mg
- Purity, sample 2: 99.414%
- Test date: September 15, 2026
- View laboratory report
House of Peptides maintains an established testing and sampling protocol with its suppliers. Under this agreed protocol, samples are randomly selected from a production batch and submitted for independent laboratory analysis.
The submitted samples are drawn from the same production batch as the corresponding inventory supplied to House of Peptides. This batch-based sampling approach provides analytical information associated with the production batch rather than individual testing of every vial.
House of Peptides may maintain inventory from multiple production batches of the same compound. Each Certificate of Analysis corresponds to its identified batch, which may be distinguished by cap color or lot designation. Orders are fulfilled on a first-in, first-out (FIFO) basis, so the batch supplied depends on available inventory at the time of fulfillment. Laboratory findings apply to the submitted samples from their respective batches, not to every individual vial.
Scientific Research Background
Tirzepatide acts on two hormone receptors involved in metabolism: GIP and GLP-1.
These hormones help the body respond to food by influencing blood sugar regulation, insulin release, and appetite.
Researchers have studied how activating both pathways affects blood sugar and body weight. Large clinical trials have reported changes in these measurements among participants receiving pharmaceutical tirzepatide.
Those findings apply to the specific medications studied and do not establish equivalent results for independently sourced research materials.
Tirzepatide is the active ingredient in FDA-approved prescription medicines, including Mounjaro and Zepbound. Those approvals apply to the respective prescription products and indications, not to House of Peptides' separately sourced Tirzepatide 30mg research product.
Compound details
- Research classification: Dual GIP / GLP-1 receptor agonist
Clinical Research Observations
1. Why is tirzepatide studied in metabolic research?
Tirzepatide acts on GIP and GLP-1 receptors, which are involved in metabolic signaling.
What researchers found: Clinical studies have reported changes in blood sugar and body weight in the populations studied.
Why it matters: These findings help researchers understand how the two hormone pathways influence metabolism.
2. What have human studies found about body weight?
Large clinical trials have investigated tirzepatide in adults with obesity or overweight and related conditions.
What researchers found: In a 72-week trial involving more than 2,500 adults, mean weight reductions ranged from 15.0% to 20.9% across tirzepatide groups, compared with 3.1% for placebo.
Why it matters: The results describe outcomes for the studied populations and medicines used in the studies, not predictions for individuals or independently sourced products.
3. What adverse effects were observed?
Researchers tracked adverse events throughout clinical trials.
What researchers found: Nausea, diarrhea, and vomiting were among the commonly reported adverse effects.
Why it matters: Understanding adverse effects is essential to evaluating a treatment's overall clinical evidence.
4. Can these findings be applied to HOP research vials?
Published trials used defined medicines prepared for the studies under controlled conditions.
What researchers found: The studies established findings for the specific materials and populations investigated.
Why it matters: They do not establish that independently sourced research vials have equivalent quality, safety, or clinical effects.
Published Scientific Research
- Frías et al. (2018), Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial, The Lancet. https://doi.org/10.1016/S0140-6736(18)32260-8
- Jastreboff et al. (2022), Tirzepatide Once Weekly for the Treatment of Obesity, New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2206038
Understanding the Research Findings
Independent laboratory analysis of submitted samples associated with House of Peptides’ Tirzepatide 30mg inventory reported identification of tirzepatide.
The clinical findings above relate to pharmaceutical materials evaluated in Eli Lilly’s studies. Identifying the compound does not establish identical formulation, pharmaceutical quality, safety, or clinical outcomes. Although tirzepatide is an active ingredient in FDA-approved medications, House of Peptides’ research product is not FDA-approved or represented as interchangeable or clinically equivalent to those medications.
House of Peptides is not affiliated with or endorsed by Eli Lilly and Company.
Research Use Notice
For laboratory research only. Not intended for human or veterinary administration, diagnostic, or therapeutic use.
Reviews
There are no reviews yet.